- Home
- NTIP vs BOLD Comparison
NTIP vs BOLD Comparison
Compare NTIP & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- BOLD
- Stock Information
- Founded
- NTIP 1990
- BOLD 2018
- Country
- NTIP United States
- BOLD United States
- Employees
- NTIP N/A
- BOLD N/A
- Industry
- NTIP Multi-Sector Companies
- BOLD
- Sector
- NTIP Miscellaneous
- BOLD
- Exchange
- NTIP Nasdaq
- BOLD Nasdaq
- Market Cap
- NTIP 32.0M
- BOLD 24.4M
- IPO Year
- NTIP 1998
- BOLD 2024
- Fundamental
- Price
- NTIP $1.42
- BOLD $1.19
- Analyst Decision
- NTIP
- BOLD Buy
- Analyst Count
- NTIP 0
- BOLD 3
- Target Price
- NTIP N/A
- BOLD $4.00
- AVG Volume (30 Days)
- NTIP 35.4K
- BOLD 105.1K
- Earning Date
- NTIP 08-11-2025
- BOLD 08-11-2025
- Dividend Yield
- NTIP 7.07%
- BOLD N/A
- EPS Growth
- NTIP N/A
- BOLD N/A
- EPS
- NTIP N/A
- BOLD N/A
- Revenue
- NTIP $250,000.00
- BOLD N/A
- Revenue This Year
- NTIP N/A
- BOLD N/A
- Revenue Next Year
- NTIP N/A
- BOLD N/A
- P/E Ratio
- NTIP N/A
- BOLD N/A
- Revenue Growth
- NTIP N/A
- BOLD N/A
- 52 Week Low
- NTIP $1.16
- BOLD $1.00
- 52 Week High
- NTIP $1.78
- BOLD $4.72
- Technical
- Relative Strength Index (RSI)
- NTIP 63.69
- BOLD N/A
- Support Level
- NTIP $1.40
- BOLD N/A
- Resistance Level
- NTIP $1.46
- BOLD N/A
- Average True Range (ATR)
- NTIP 0.05
- BOLD 0.00
- MACD
- NTIP 0.00
- BOLD 0.00
- Stochastic Oscillator
- NTIP 78.95
- BOLD 0.00
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.